NEW YORK (GenomeWeb News) – The US Food and Drug Administration has cleared Cepheid's Xpert CT/NG test for marketing, the Sunnyvale, Calif.-based company announced after the close of the market on Thursday.

The test for the rapid detection and differentiation of chlamydia and Neisseria gonorrhoeae runs on Cepheid's GeneXpert system and allows for the same-day patient consultation and treatment of the two most common sexually transmitted bacterial infections in the US.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.